TuHURA Biosciences, Inc.
As of Oct 22, 2026, TuHURA Biosciences is in Stage 3, the topping phase, now in week 14 (since Jul 16, 2026). It closed at $2.01, 36.2% below its 52-week high and above its 200-day average, which is rising.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is HURA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
HURA among Biotechnology220th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …220 | HURA | Stage 3 · wk 14 | 45 | −2.0% |
TuHURA Biosciences: quick answers
What stage is TuHURA Biosciences in?
As of Oct 22, 2026, TuHURA Biosciences (HURA) is in Stage 3, the topping phase. It entered Stage 3 on Jul 16, 2026 and is in week 14. What the four stages mean
Is TuHURA Biosciences in an uptrend?
Its uptrend has stalled. TuHURA Biosciences is in Stage 3, the topping phase that follows an advance. It trades 4.0% above its 200-day average, which is rising.
How far is TuHURA Biosciences from its 52-week high?
TuHURA Biosciences closed at $2.01 on Oct 22, 2026, 36.2% below its 52-week high of $3.15. Its 52-week low is $0.44.
How has TuHURA Biosciences performed over the past year?
As of Oct 22, 2026, TuHURA Biosciences is down 13.0% over the past year and up 168.0% so far in 2026.
Which sector and industry is TuHURA Biosciences in?
TuHURA Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.